Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (5247)	1/5/1998 7:45:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Tharos,excellent note. Biostock1-all those indications are more or less components of sepsis. I think few will deny that if we get a approval and some positive clinical we will see off label use. Also rumor is "that is r-u-m-o-r" that fda wanted a spesis trial. U have no idea if its true or not. btw-back to tharos.- I think interest rates could have a bigger impact than even pe. Asia is wild,wild card. (japan and 14,000 nikki)